Success! You're on the list.

Success! You're on the list.
London Tech Week

Curebase secures $40M for its decentralised clinical trials and patient-centric software

Image credits: Curebase

Curebase, a San Francisco-based provider of decentralised clinical research software solutions, has secured $40 million in Series B funding. With this round, the startup has raised total funding of $59 million.

Investors in Curebase

The financing round was led by Industry Ventures along with participation from new institutional investors Acrew Capital (which invested in Banked, Grain, and Silverfort recently), World Innovation Lab and Positive Sum, and existing investors GGV Capital (which led Curebase’s Series A round), Bold Capital and Xfund.

The financing round also included a strategic investment by global biopharmaceutical company Gilead Sciences. Also, Gaingels, an investment syndicate that focuses on startups dedicated to building diverse and inclusive teams participated in the round.

Curebase will use the investment will deepen its breadth of capabilities beyond the virtual experience via more complex site and community healthcare interfaces, a richer range of clinical software and services, and more robust capabilities for interventional drug sponsors and global studies.

“We look to invest in technology companies that we believe are transforming massive, inefficient industries,” said Fanni Fan, vice president at Industry Ventures. “Curebase stood out to us for its full-vertical approach, comprehensive patient-centric software platform, and outstanding response from customers. We believe this investment will allow them to scale their model in a market that is rapidly growing on a global level, and continue expanding into the most complex drug study designs.”

“It is more urgent than ever for the biopharmaceutical industry to transform the design and execution of our clinical programs so that we radically change the way patients experience clinical trials. We believe that by taking a human-centered design and technology enabled approach – as Curebase does – we can co-design a process that more effectively brings treatment options to people in need,” said Matt Bryant, Head of Technology and Innovation at Gilead Sciences. “Curebase’s approach will help to improve the quality, speed and patient diversity of clinical trials so that we have a more representative population in our clinical research.”

“We are pleased that investors are recognizing that Curebase is more than a software platform,” said company founder and CEO Tom Lemberg. “We are an end-to-end clinical trial company with global capabilities and an extensive site network of virtual and hybrid site staff that provides everything needed to successfully execute a better clinical trial.”

Democratises access to clinical studies

Curebase was established in 2017 by Tom Lemberg in San Francisco. It builds a digital clinical trial assistant that would alter the way medical providers discover, activate, and administer clinical trials for their patients. It aims to run clinical trials faster and cheaper than anyone else via software to reduce recruitment times, automate manual steps, and let drug companies distribute their trials to clinics.

It is touted to be a decentralised clinical trials (DCTs) and patient-centric clinical trial software. The company’s mission is to bring quality medical innovations to patients faster and improve human wellbeing through more efficient clinical studies. Curebase reinvents clinical trials and research by using cutting-edge clinical software and remote study management techniques.

With its cutting-edge approach, the company allows patients to participate at home and with community physicians leading to faster, cost effective, and diverse studies. Curebase has a unique combination of in-house virtual CRCs paired with a global network of virtual PIs working together with community doctors to bring studies to patients anywhere.

Related Posts

Get daily funding news briefings in the tech world delivered right to your inbox.

Enter Your Email
join our newsletter. thank you